Sickle-Cell Anemia Therapeutics Market in the US 2018-2022

Sickle-cell anemia treatment is associated with high cost medications in the US. To reduce the treatment burden on the patients, several companies and government organizations are offering reimbursement for the treatment. Several stakeholders are offering partnerships to work with state and local policyholders and the payer group to ensure the payment and reimbursement are in place so that the providers can be supported to advance access to quality care. The analysts have predicted that the sickle-cell anemia therapeutics market in the US will register a CAGR of over 15% by 2022.

Market Overview

Recent product approvals for sickle-cell anemia

Due to fewer product availability in the US for the treatment of sickle-cell anemia, hence these recently approved products drive the market over the forecast period.

Limited number of approved drugs

The availability of very limited approved therapies for the treatment of sickle-cell anemia id the US is expected to hamper the growth of the market during our forecast period.

For the detailed list of factors that will drive and challenge the growth of the sickle-cell anemia therapeutics market in the US during the 2018-2022, view this report.

Competitive Landscape

The sickle-cell anemia therapeutics market in the US is highly concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORTPART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 05: MARKET SIZING

Market definition

Market sizing 2017

Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 07: MARKET SEGMENTATION BY THERAPY

Segmentation by therapy

Comparison by therapy

Hydroxyurea - Market size and forecast 2017-2022

L-glutamine therapy- Market size and forecast 2017-2022

Market opportunity by therapy

PART 08: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Introduction of gene therapy

Strategic alliances

Orphan drug designations for sickle-cell anemia

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bristol-Myers Squibb

Emmaus Medical

Medunik USA

PART 14: APPENDIX

List of abbreviations

List of Exhibits

Exhibit 01: Parent market
Exhibit 02: Global hematology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Therapy - Market share 2017-2022 (%)
Exhibit 19: Comparison by therapy
Exhibit 20: Hydroxyurea - Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Hydroxyurea - Year-over-year growth 2018-2022 (%)
Exhibit 22: L-glutamine therapy - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: L-glutamine therapy - Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by therapy
Exhibit 25: Customer landscape
Exhibit 26: Vendor landscape
Exhibit 27: Landscape disruption
Exhibit 28: Vendors covered
Exhibit 29: Vendor classification
Exhibit 30: Market positioning of vendors
Exhibit 31: Bristol-Myers Squibb - Overview
Exhibit 32: Bristol-Myers Squibb - Business segments
Exhibit 33: Bristol-Myers Squibb - Organizational developments
Exhibit 34: Bristol-Myers Squibb - Geographic focus
Exhibit 35: Bristol-Myers Squibb - Segment focus
Exhibit 36: Bristol-Myers Squibb - Key offerings
Exhibit 37: Bristol-Myers Squibb - Key customers
Exhibit 38: Emmaus Medical - Overview
Exhibit 39: Emmaus Medical - Organizational developments
Exhibit 40: Emmaus Medical - Geographic focus
Exhibit 41: Emmaus Medical - Key offerings
Exhibit 42: Emmaus Medical - Key customers
Exhibit 43: Medunik USA - Overview
Exhibit 44: Medunik USA - Organizational developments
Exhibit 45: Medunik USA - Key offerings
Exhibit 46: Medunik USA - Key customers

Executive Summary

Sickle-Cell Anemia Therapeutics Market in the US 2018-2022

The analyst recognizes the following companies as the key players in the sickle-cell anemia therapeutics market in the US: Bristol-Myers Squibb, Emmaus Medical, Medunik USA.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the research on the development of gene therapy to treat sickle-cell anemia is a new approach.

According to the report, one of the major drivers for this market is the awareness’s programs are expected to increase the focus on disease diagnosis and treatment options. Therefore, leading to the growth of the sickle-cell anemia therapeutics market in the US over the forecast period.

Further, the report states that one of the major factors hindering the growth of this market is the stringent government regulations for marketing approval are expected to restrict the market growth during the forecast period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.